CHARLESTON, S.C., Oct. 10, 2011 (GLOBE NEWSWIRE) -- Revolutions Medical Corporation ("Revolutions Medical" or the "Company") plans to donate RevVac auto retractable safety syringes to the Israeli Izhar Project (the "Izhar Project" or "Project"), an innovative needle disposal pilot program. The Izhar Project was initiated in 2003 by the Israeli Ministry of Health to combat drug use. The Project particularly aims to eliminate the re-use of contaminated needles, while ensuring their safe disposal. The Project will be conducted by M.S.W Daniel Gold, who leads the Project. The Project's delivery posts are located throughout Israel and allow habitual drug users to hand in older syringes and receive new ones. The overarching goal of the Izhar Project is to ensure the streets are free and clear from potentially contaminated syringes.
Ron Wheet, Chief Executive Officer and Chairman of Revolutions Medical, stated, "Not only will our RevVac safety syringes decrease accidental needle sticks, but once the safety mechanism is activated, the syringes cannot be reused. This will limit exposure to contaminated needles and reduce hazardous disposable waste costs. At Revolutions Medical, we are eager to help countries that see the benefits of our syringe in reducing the spread of contagious blood-borne diseases by contributing initial syringes to compatible pilot programs."
"The enthusiasm regarding the RevVac safety syringe pilot program is tremendous and the desire of Revolutions Medical to help Israel reduce the spread of HIV, Hepatitis B and C, tuberculosis and other diseases will greatly benefit all parties involved," stated Aviv Oreg, President of CeifiT, Ltd., Revolutions Medical's distributor in Israel.
The Izhar Project, which annually replaces between 200,000 and 250,000 syringes, was implemented in 2003 and is funded by five key areas: the Addiction Department and the Tuberculosis and AIDS Department, which reside within Israeli Ministry of Health; the Israeli Authority for Combating Drugs and Alcohol Abuse; the Rashi Foundation; and the Israeli Committee for Combating AIDS. Representatives of these five areas form a committee that is responsible for setting directive policies. The RevVac pilot program is expected to launch in November 2011. This pilot program represents the first step of cooperation between Revolutions Medical and Israeli medical institutions.
About Revolutions Medical Corporation
Revolutions Medical is a safety medical device and software application company. Its products include the RevVac™ Safety Syringe (FDA cleared), safety blood drawing device, the RevColor™, RevDisplay™ and Rev3D™ software tools that are compatible with standard MRIs and standard Picture Archiving Computer Systems (PACS).
For additional information, please visit Revolutions Medical corporate website:
http://www.revolutionsmedical.com
To be added to the Revolutions Medical investor email list, please email:
investment@revolutionsmedical.com with RMCP in the subject line.
FORWARD-LOOKING STATEMENTS
The information contained herein includes forward-looking statements. These statements relate to future events or to our future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond our control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects our current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to our operations, results of operations, growth strategy and liquidity. We assume no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.